中国处方药
中國處方藥
중국처방약
Journal Of China Prescription Drug
2015年
10期
14-15
,共2页
磺脲类降糖药物继发失效%甘精胰岛素%精蛋白锌重组赖脯胰岛素混和注射液%二甲双胍
磺脲類降糖藥物繼髮失效%甘精胰島素%精蛋白鋅重組賴脯胰島素混和註射液%二甲雙胍
광뇨류강당약물계발실효%감정이도소%정단백자중조뢰포이도소혼화주사액%이갑쌍고
Type 2 diabetes with secondary failure caused by the treatment of drugsulfonylurea antidiabetic drugs%Humalog 25%Metformin
目的 探讨甘精胰岛素或精蛋白锌重组赖脯胰岛素混和注射液分别联合二甲双胍治疗经磺脲类降糖药物治疗继发失效的2型糖尿病的临床疗效和安全性.方法 2011年3月~2012年11月期间收治的磺脲类降糖药物继发失效的2型糖尿病50例为研究对象,A组患者给予精蛋白锌重组赖脯胰岛素混和注射液(优泌乐25)联合二甲双胍进行治疗;B组患者给予甘精胰岛素联合二甲双胍进行治疗,治疗3个月后,比较两组患者的临床治疗效果.结果 治疗完成后,两组患者的体重均有不同程度的增加,但是前后比较差异无统计学意义(P>0.05);精蛋白锌重组赖脯胰岛素混和注射液联合二甲双胍治疗组在早、中、晚饭后2 hPBG的控制上优于甘精胰岛素联合二甲双胍治疗组(P<0.05),而在FBG水平的控制稍逊甘精胰岛素联合二甲双胍治疗组,但未见明显统计学差异(P>0.05).经治疗,精蛋白锌重组赖脯胰岛素混和注射液联合二甲双胍治疗组的糖化血红蛋白低于甘精胰岛素联合二甲双胍治疗组,组间差异具有统计学意义(P<0.05).结论 在磺脲类降糖药物继发失效的治疗中,优泌乐25联合二甲双胍治疗效果更好.
目的 探討甘精胰島素或精蛋白鋅重組賴脯胰島素混和註射液分彆聯閤二甲雙胍治療經磺脲類降糖藥物治療繼髮失效的2型糖尿病的臨床療效和安全性.方法 2011年3月~2012年11月期間收治的磺脲類降糖藥物繼髮失效的2型糖尿病50例為研究對象,A組患者給予精蛋白鋅重組賴脯胰島素混和註射液(優泌樂25)聯閤二甲雙胍進行治療;B組患者給予甘精胰島素聯閤二甲雙胍進行治療,治療3箇月後,比較兩組患者的臨床治療效果.結果 治療完成後,兩組患者的體重均有不同程度的增加,但是前後比較差異無統計學意義(P>0.05);精蛋白鋅重組賴脯胰島素混和註射液聯閤二甲雙胍治療組在早、中、晚飯後2 hPBG的控製上優于甘精胰島素聯閤二甲雙胍治療組(P<0.05),而在FBG水平的控製稍遜甘精胰島素聯閤二甲雙胍治療組,但未見明顯統計學差異(P>0.05).經治療,精蛋白鋅重組賴脯胰島素混和註射液聯閤二甲雙胍治療組的糖化血紅蛋白低于甘精胰島素聯閤二甲雙胍治療組,組間差異具有統計學意義(P<0.05).結論 在磺脲類降糖藥物繼髮失效的治療中,優泌樂25聯閤二甲雙胍治療效果更好.
목적 탐토감정이도소혹정단백자중조뢰포이도소혼화주사액분별연합이갑쌍고치료경광뇨류강당약물치료계발실효적2형당뇨병적림상료효화안전성.방법 2011년3월~2012년11월기간수치적광뇨류강당약물계발실효적2형당뇨병50례위연구대상,A조환자급여정단백자중조뢰포이도소혼화주사액(우비악25)연합이갑쌍고진행치료;B조환자급여감정이도소연합이갑쌍고진행치료,치료3개월후,비교량조환자적림상치료효과.결과 치료완성후,량조환자적체중균유불동정도적증가,단시전후비교차이무통계학의의(P>0.05);정단백자중조뢰포이도소혼화주사액연합이갑쌍고치료조재조、중、만반후2 hPBG적공제상우우감정이도소연합이갑쌍고치료조(P<0.05),이재FBG수평적공제초손감정이도소연합이갑쌍고치료조,단미견명현통계학차이(P>0.05).경치료,정단백자중조뢰포이도소혼화주사액연합이갑쌍고치료조적당화혈홍단백저우감정이도소연합이갑쌍고치료조,조간차이구유통계학의의(P<0.05).결론 재광뇨류강당약물계발실효적치료중,우비악25연합이갑쌍고치료효과경호.
Objective To observe the clinical efficacy of Gan insulin glargine or Humalog 25 respectively combined with metformin treatment in type 2 diabetes with secondary failure caused by the treatment of drugsulfonylurea antidiabetic drugs. Comparing the safety and effectiveness of the two groups of patientsMethods From March 2011 to November 2012, 50 cases of type 2 diabetes patients with secondary failure caused by the treatment of drug sulfonylurea antidiabetic were selected as the objects for the study, 25 cases in each. Patients in group A were given protamine zinc recombinant human insulin lispro mixed injection(Humalog 25) in combination with metformin treatment; group B patients were given Gan insulin glargine combined with metformin treatment, and 3 months after treatment, compared two groups of patients with clinical treatmentResults After treatment, the body weight of the two groups increased significantly, but the difference was not statistically significant(P>0.05); the 2 hPBG level in group A were superior better than that group B(P<0.05), but not the FBG level(P>0.05).Conclusion In the treatment of secondary failure of the drug, the effect of protamine zinc recombinant human insulin lispro mixed injection(Humalog 25) in combination with metformin treatment was better.
